Apexigen, Inc.

Apexigen, Inc. (Nasdaq: APGN) is a clinical-stage biopharmaceutical company focused on oncology antibody therapeutics that reached public markets through a de-SPAC merger with Brookline Capital Acquisition Corp., a blank-check vehicle sponsored by Brookline Capital Markets. The SPAC completed its IPO in 2021, targeting the healthcare and life sciences sector. An 8-K current report filed with the SEC on April 26, 2022 under accession number 0001193125-22-120446 reflects activity tied to the business combination process. The combined company operates in the clinical-stage biopharmaceutical space with a pipeline centered on cancer immunology. Sign up at SpacDesk for full filing history, sponsor profiles, and deal analytics on Apexigen and hundreds of other SPAC transactions.